Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations

Agazie, 2003, Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling, Mol. Cell. Biol., 23, 7875, 10.1128/MCB.23.21.7875-7886.2003 Akashi, 2000, A clonogenic common myeloid progenitor that gives rise to all myeloid lineages, Nature, 404, 193, 10.1038/35004599 Araki, 2003, Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors, J. Biol. Chem., 278, 41677, 10.1074/jbc.M306461200 Araki, 2004, Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation, Nat. Med., 10, 849, 10.1038/nm1084 Arico, 1997, Juvenile myelomonocytic leukemia, Blood, 90, 479, 10.1182/blood.V90.2.479 Armstrong, 2003, MLL-rearranged leukemias: Insights from gene expression profiling, Semin. Hematol., 40, 268, 10.1016/S0037-1963(03)00196-3 Asha, 2003, Analysis of Ras-induced overproliferation in Drosophila hemocytes, Genetics, 163, 203, 10.1093/genetics/163.1.203 Bader-Meunier, 1997, Occurrence of myeloproliferative disorder in patients with Noonan syndrome, J. Pediatr., 130, 885, 10.1016/S0022-3476(97)70273-7 Barford, 1998, Revealing mechanisms for SH2 domain-mediated regulation of the protein tyrosine phosphatase SHP-2, Structure, 6, 249, 10.1016/S0969-2126(98)00027-6 Bennett, 1994, Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras, Proc. Natl. Acad. Sci. USA, 91, 7335, 10.1073/pnas.91.15.7335 Bentires-Alj, 2004, Activating mutations of the Noonan Syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult AML, Cancer Res., 64, 8816, 10.1158/0008-5472.CAN-04-1923 Bjornsti, 2004, The TOR pathway: A target for cancer therapy, Nat. Rev. Cancer, 4, 335, 10.1038/nrc1362 Bollag, 1996, Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in hematopoietic cells, Nat. Genet., 12, 144, 10.1038/ng0296-144 Brand, 1993, Targeted gene expression as a means of altering cell fates and generating dominant phenotypes, Development, 118, 401, 10.1242/dev.118.2.401 Braun, 2004, Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder, Proc. Natl. Acad. Sci. USA, 101, 597, 10.1073/pnas.0307203101 Chan, 2004, Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease, J. Clin. Invest., 113, 528, 10.1172/JCI20476 Choong, 1999, Juvenile myelomonocytic leukemia and Noonan Syndrome, J. Pediatr. Hematol. Oncol., 21, 523, 10.1097/00043426-199911000-00014 Cichowski, 2003, Dynamic regulation of the ras pathway via proteolysis of the NF1 tumor suppressor, Genes Dev., 17, 449, 10.1101/gad.1054703 Cross, 2002, Tyrosine kinase fusion genes in chronic myeloproliferative diseases, Leukemia, 16, 1207, 10.1038/sj.leu.2402556 Dearolf, 1998, Fruit fly “leukemia.”, Biochim. Biophys. Acta, 1377, M13 Denu, 1996, Form and function in protein dephosphorylation, Cell, 87, 361, 10.1016/S0092-8674(00)81356-2 Donovan, 2002, Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation and cytokine expression in Nf1-deficient myeloid cells, Cancer Cell, 2, 507, 10.1016/S1535-6108(02)00214-3 Emanuel, 1996, Juvenile myelomonocytic leukemia: Molecular undrestanding and prospects for therapy, Mol. Med. Today, 2, 468, 10.1016/1357-4310(96)10044-7 Flint, 1997, Development of “substrate-trapping” mutants to identify physiological substrates of protein tyrosine phosphatases, Proc. Natl. Acad. Sci. USA, 94, 1680, 10.1073/pnas.94.5.1680 Freeman, 1992, Identification of a human src-homology 2 (SH2) containing tyrosine phosphatase: A putative homolog of Drosophila corkscrew, Proc. Natl. Acad. Sci. USA, 89, 11239, 10.1073/pnas.89.23.11239 Gilliland, 2002, Role of FLT3 in leukemia, Curr. Opin. Hematol., 9, 274, 10.1097/00062752-200207000-00003 Gilliland, 2002, Focus on acute leukemias, Cancer Cell, 1, 417, 10.1016/S1535-6108(02)00081-8 Goldfine, 1995, Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies, J. Clin. Endocrinol. Metab., 80, 3311 Gu, 2003, The 'Gab' in signal transduction, Trends Cell Biol., 13, 122, 10.1016/S0962-8924(03)00002-3 Gu, 1997, Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells, J. Biol. Chem., 272, 16421, 10.1074/jbc.272.26.16421 Gu, 2001, Essential role for Gab2 in the allergic response, Nature, 412, 186, 10.1038/35084076 Hanafusa, 2004, Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty, J. Biol. Chem., 279, 22992, 10.1074/jbc.M312498200 Harrison, 1995, Activation of a Drosophila Janus Kinase (JAK) causes hematopoietic neoplasia and developmental defects, EMBO J., 14, 2857, 10.1002/j.1460-2075.1995.tb07285.x Hawley, 1994, Versatile retroviral vectors for potential use in gene therapy, Gene Ther., 1, 136 Hof, 1998, Crystal structure of the SH2 domain phosphatase SHP-2, Cell, 98, 441, 10.1016/S0092-8674(00)80938-1 Howe, 1992, Activation of the MAP kinase pathway by the protein kinase raf, Cell, 71, 335, 10.1016/0092-8674(92)90361-F Ingram, 2001, Hyperactivation of p21ras and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro, J. Exp. Med., 194, 57, 10.1084/jem.194.1.57 Khwaja, 1997, Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway, EMBO J., 16, 2783, 10.1093/emboj/16.10.2783 Klinghoffer, 1995, Identification of a putative Syp substrate, the PDGFB receptor, J. Biol. Chem., 270, 22208, 10.1074/jbc.270.38.22208 Largaespada, 1996, Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia, Nat. Genet., 12, 137, 10.1038/ng0296-137 Le, 2004, Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder, Blood, 103, 4243, 10.1182/blood-2003-08-2650 Leevers, 1992, Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein, EMBO J., 11, 569, 10.1002/j.1460-2075.1992.tb05088.x Li, 1994, A new function for a phosphotyrosine phosphatase: Linking GRB2-Sos to a receptor tyrosine kinase, Mol. Cell. Biol., 14, 509, 10.1128/MCB.14.1.509 Liu, 2002, The Gift of Gab, FEBS Lett., 515, 1, 10.1016/S0014-5793(02)02425-0 Loh, 2004, Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis, Blood, 103, 2325, 10.1182/blood-2003-09-3287 Lu, 2001, Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling, Mol. Cell, 8, 759, 10.1016/S1097-2765(01)00369-0 Luo, 1995, An amino acid substitution in the Drosophila hoptum-l Jak kinase causes leukemia-like hematopoietic defects, EMBO J., 14, 1412, 10.1002/j.1460-2075.1995.tb07127.x MacDonald, 2000, Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus, Clin. Ther., 22, B101, 10.1016/S0149-2918(00)89027-X Meister, 2004, Blood cells of Drosophilla: Cell lineages and role in host defence, Curr. Opin. Immunol., 16, 10, 10.1016/j.coi.2003.11.002 Million, 2000, The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase, Blood, 96, 664, 10.1182/blood.V96.2.664 Mohi, 2004, Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs, Proc. Natl. Acad. Sci. USA, 101, 3130, 10.1073/pnas.0400063101 Neel, 2003, The “Shp”ing news: SH2 domain-containing tyrosine phosphatases in cell signaling, Trends Biochem. Sci., 28, 284, 10.1016/S0968-0004(03)00091-4 Nishida, 2002, Requirement of Gab2 for mast cell development and KitL/c-Kit signaling, Blood, 99, 1866, 10.1182/blood.V99.5.1866 O'Reilly, 1999, Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps, Mol. Cell. Biol., 20, 299, 10.1128/MCB.20.1.299-311.2000 Pardanani, 2004, Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders, Blood, 104, 1931, 10.1182/blood-2004-01-0246 Pawson, 1997, Signaling through scaffold, anchoring and adapter proteins, Science, 278, 2075, 10.1126/science.278.5346.2075 Perkins, 1992, corkscrew encodes a putative tyrosine phosphatase that functions to transduce the terminal signal from the receptor tyrosine kinase torso, Cell, 70, 225, 10.1016/0092-8674(92)90098-W Ren, 2004, Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor, J. Biol. Chem., 279, 8497, 10.1074/jbc.M312575200 Sarkozy, 2003, Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes, J. Med. Genet., 40, 704, 10.1136/jmg.40.9.704 Sattler, 2002, Critical role for Gab2 in transformation by BCR/ABL, Cancer Cell, 1, 479, 10.1016/S1535-6108(02)00074-0 Sawyers, 1999, Chronic myeloid leukemia, N. Engl. J. Med., 340, 1330, 10.1056/NEJM199904293401706 Schwaller, 1998, Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes, EMBO J., 17, 5321, 10.1093/emboj/17.18.5321 Sebolt-Leopold, 2000, Development of anticancer drugs targeting the MAP kinase pathway, Oncogene, 19, 6594, 10.1038/sj.onc.1204083 Side, 1997, Myeloid disorders in infants with Noonan syndrome and a resident's “rule” recalled, J. Pediatr., 130, 857 Tartaglia, 2001, Mutations in PTPN11, encoding protein tyrosine phosphatase SHP-2, cause Noonan syndrome, Nat. Genet., 29, 465, 10.1038/ng772 Tartaglia, 2002, PTPN11 mutations in Noonan syndrome: Molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity, Am. J. Hum. Genet., 70, 1555, 10.1086/340847 Tartaglia, 2003, Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia, Nat. Genet., 34, 148, 10.1038/ng1156 Tartaglia, 2004, Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia, Blood, 104, 307, 10.1182/blood-2003-11-3876 Tonks, 2001, Combinatorial control of specificity by protein-tyrosine phosphatases, Curr. Opin. Cell Biol., 13, 182, 10.1016/S0955-0674(00)00196-4 Van Vactor, 1998, Genetic analysis of protein tyrosine phosphatases, Curr. Opin. Genet. Dev., 8, 112, 10.1016/S0959-437X(98)80070-1 Welham, 1994, Interleukin (IL)-3 and granulocyte/macrophage colony-stimulating factor, but not IL-4, induce tyrosine phosphorylation, activation, and association of SHPTP2 with Grb2 and phosphatidylinositol 3′-kinase, J. Biol. Chem., 269, 23764, 10.1016/S0021-9258(17)31581-8 Wilhelm, 2004, BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res., 64, 7099, 10.1158/0008-5472.CAN-04-1443 Zatkova, 2004, Distinct sequences on 11q13.5 and 11q23–24 are frequently coamplified with MLL in complexly organized 11q amplicons in AML/MDS patients, Genes Chromosomes Cancer, 39, 263, 10.1002/gcc.20002 Zhang, 1998, Nf1 regulates hematopoietic progenitor cell growth and Ras signaling in response to multiple cytokines, J. Exp. Med., 187, 1893, 10.1084/jem.187.11.1893 Zhang, 2002, Receptor-specific regulation of phosphatidyl 3′-kinase activation by the protein tyrosine phosphatase Shp2, Mol. Cell. Biol., 22, 4062, 10.1128/MCB.22.12.4062-4072.2002 Zhang, 2004, Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment, Mol. Cell, 13, 341, 10.1016/S1097-2765(04)00050-4 Zinyk, 1993, Drosophila awdK-pn, a homologue of the metastasis suppressor gene nm23, suppresses the Tum-l hematopoietic oncogene, Nat. Genet., 4, 195, 10.1038/ng0693-195